uniQure (NASDAQ:QURE) Shares Up 3.9% – Time to Buy?

uniQure (NASDAQ:QURE)’s share price shot up 3.9% during mid-day trading on Tuesday . The company traded as high as $9.66 and last traded at $9.53. 71,205 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 1,676,247 shares. The stock had previously closed at $9.17.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. StockNews.com upgraded uniQure to a “sell” rating in a research report on Tuesday, March 11th. Mizuho increased their price objective on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of uniQure in a report on Tuesday, March 4th. Wells Fargo & Company decreased their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Finally, Chardan Capital assumed coverage on uniQure in a research note on Tuesday, April 1st. They set a “buy” rating and a $38.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.80.

uniQure Stock Up 3.4 %

The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $512.65 million, a price-to-earnings ratio of -1.91 and a beta of 0.42. The stock has a 50-day moving average of $12.14 and a 200-day moving average of $11.14.

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the transaction, the chief financial officer now owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now owns 651,454 shares of the company’s stock, valued at $6,703,461.66. This trade represents a 4.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock valued at $961,401 in the last three months. 4.74% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several large investors have recently bought and sold shares of QURE. FMR LLC raised its holdings in shares of uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after buying an additional 346,274 shares in the last quarter. Sanders Morris Harris LLC boosted its position in uniQure by 50.0% in the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after buying an additional 34,034 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of uniQure during the third quarter worth approximately $7,360,000. Y Intercept Hong Kong Ltd bought a new position in shares of uniQure in the third quarter valued at approximately $283,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of uniQure in the 4th quarter worth approximately $320,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.